Swiss drugs maker Novartis says its Indian subsidiary will continue to file patents for new drugs in India despite the rejection of its plea for patent protection for its anti-cancer treatment Gilvec.
Novartis' seven-year legal battle failed after India's Supreme Court ruled it was it was an amended version of an existing compound.
... No Comment | euronews: watch the international news without commentary | http://www.euronews.net/nocomment/
Écris le tout premier commentaire